Cargando…

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Mann, Douglas L., Kelly, Daniel P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034482/ https://www.ncbi.nlm.nih.gov/pubmed/30062156 http://dx.doi.org/10.1016/j.jacbts.2017.07.004

Ejemplares similares

The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
por: Ha, Chae-Myeong, et al.
Publicado: (2019)

Oxytocin: A New Therapeutic for Heart Failure?
por: Habecker, Beth A.
Publicado: (2020)

Unraveling the Mechanisms by Which Calpain Inhibition Prevents Heart Failure Development
por: Wehrens, Xander H.T.
Publicado: (2018)

Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

The Role of Macrophages in Nonischemic Heart Failure
por: Chen, Bijun, et al.
Publicado: (2018)

A Growth Tonic for Heart Failure?
por: Bishopric, Nanette H.
Publicado: (2016)

Reversing Heart Failure With a Ventricular Anchoring Device: Another Hope for Myopathic Mitral Regurgitation
por: Rame, J. Eduardo
Publicado: (2020)

Heart Failure With Preserved Ejection Fraction in Women: New Clues to Causes and Treatment
por: Barton, Matthias, et al.
Publicado: (2020)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

Reconsidering Renal Sympathetic Denervation for Heart Failure
por: Tang, W.H. Wilson, et al.
Publicado: (2017)

Brain-derived neurotrophic factor in heart failure
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

Abnormal heart rate recovery in patients with heart failure: an important target for exercise training treatment
por: Dimopoulos, Stavros
Publicado: (2015)

Cell Therapy for Heart Failure With Preserved Ejection Fraction
por: Borlaug, Barry A., et al.
Publicado: (2016)

Metabolic Coupling as a Therapeutic Strategy for Heart Failure
por: Young, Martin E.
Publicado: (2019)

Tissue transglutaminase in the pathogenesis of heart failure
por: Shinde, Arti V., et al.
Publicado: (2017)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
por: Kowalska, Klaudia, et al.
Publicado: (2021)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Modulation of Glucagon Signaling: A Metabolic Approach for Heart Failure?
por: Pocai, Alessandro
Publicado: (2019)

Promoting Health Equity in Heart Failure Amid a Pandemic
por: DeFilippis, Ersilia M., et al.
Publicado: (2021)

Is Protein Kinase C Inhibition the Tip of the Iceberg in New Therapeutics for Acutely Decompensated Heart Failure?
por: Pimental, David R., et al.
Publicado: (2017)

Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart Failure
por: Port, J. David, et al.
Publicado: (2016)

Does nitric oxide mediate the effects of ivabradine in patients with heart failure?
por: Mączewski, Michał
Publicado: (2018)

Role of ischemia-modified albumin in patients with acute decompensated heart failure
por: Pan, Defeng, et al.
Publicado: (2016)

Heart failure guidelines implementation: Lifting barriers using registries and networks
por: Keramida, Kalliopi, et al.
Publicado: (2020)

Understanding Heart Failure With Preserved Ejection Fraction in a Diabetic Way
por: Li, Haobo, et al.
Publicado: (2021)

A New Murine Model of Clonal Hematopoiesis Investigates JAK2(V617F) in Heart Failure
por: Patel, Aniruddh P., et al.
Publicado: (2019)

Clinical evaluation of heart failure patients: what good are biomarkers bringing us?
por: de Boer, R. A.
Publicado: (2014)

To implant or not to implant?: That is the unsolved question concerning heart failure patients with non-LBBB
por: Zarse, M., et al.
Publicado: (2015)

Follistatin-Like 1: Growing Evidence for Its Beneficial Role in Heart Failure
por: Wollert, Kai C.
Publicado: (2016)

Hydrogen Sulfide Therapy Promotes Beneficial Systemic Effects in Experimental Heart Failure
por: Nabeebaccus, Adam A., et al.
Publicado: (2018)

A new paradigm for the treatment of volume overload in heart failure-combined effect of tolvaptan with furosemide
por: Okamoto, Hiroshi
Publicado: (2013)

Pulmonary hypertension in the changing landscape of congenital heart disease: Global differences and a possible driver of end-stage heart failure
por: Van De Bruaene, A., et al.
Publicado: (2016)

Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy
por: Hoch, Melanie, et al.
Publicado: (2011)

Interleukin-1 Blockade in Acute Myocardial Infarction and Heart Failure: Getting Closer and Closer
por: Toldo, Stefano, et al.
Publicado: (2017)

Innovation in Diuretic Therapy: The Missing Ingredient for Treating Worsening Heart Failure Outside the Hospital?
por: Greene, Stephen J., et al.
Publicado: (2018)

Coronary sinus dilatation as a sign of right ventricular dysfunction in patients with heart failure
por: Park, Yong Hyun
Publicado: (2015)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
por: Biegus, Jan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bn8etmoa6b8i5p9qhlcmf5j5jh